| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | STF-62247 | GDSC1000 | pan-cancer | AAC | 0.077 | 0.02 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.076 | 0.02 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | IU1 | CTRPv2 | pan-cancer | AAC | -0.088 | 0.02 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.02 |
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | 0.074 | 0.02 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | 0.072 | 0.02 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.079 | 0.02 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.02 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.02 |